- Previous Close
0.0000 - Open
0.1500 - Bid --
- Ask --
- Day's Range
0.1500 - 0.1500 - 52 Week Range
0.0700 - 0.1500 - Volume
1,000 - Avg. Volume
0 - Market Cap (intraday)
6.487M - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date May 19, 2025 - May 23, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, an online digital platform for clinics; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. In addition, it focuses in therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, and orphan and rare diseases. Further, the company engages in the data collection and analysis of neurological disorders. Additionally, it offers drug development analytics, imaging operation, post marketing surveillance, and consultancy services; and end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc is based in London, the United Kingdom.
ixico.comRecent News: PHYOF
View MorePerformance Overview: PHYOF
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHYOF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHYOF
View MoreValuation Measures
Market Cap
9.55M
Enterprise Value
7.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.43
Price/Book (mrq)
0.27
Enterprise Value/Revenue
0.40
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-34.70%
Return on Assets (ttm)
-11.14%
Return on Equity (ttm)
-19.15%
Revenue (ttm)
5.77M
Net Income Avi to Common (ttm)
-2M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
1.79M
Total Debt/Equity (mrq)
3.32%
Levered Free Cash Flow (ttm)
-1.56M